Floatz logo

Cyclophosphamide

Male Breast Cancer

Wake Forest University Health SciencesSmall moleculePhase 2Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Male Breast Cancer cohort.

Asset / SponsorPhaseRating
FILGRASTIM
University of Washington
Phase 2BBB
Irinotecan
University of California, Irvine
Phase 2BBB
Inno-206
National Cancer Institute (NCI)
Phase 2BBB
Cediranib
University of Chicago
Phase 2BB
TAMOXIFEN
Jose Pablo Leone
Phase 3BB

View all 50 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →